Related Experiment Video
Updated: Jun 12, 2026

Protein Isolation from the Developing Embryonic Mouse Heart Valve Region
Published on: September 23, 2014
Coding and Non-Coding Transcriptomic Landscape of Aortic Complications in Marfan Syndrome
Nathasha Samali Udugampolage1, Svetlana Frolova2,3, Jacopo Taurino1
1Cardiovascular-Genetic Center, IRCCS Policlinico San Donato, 20097 Milan, Italy.
Abstract:
Marfan syndrome (MFS) is a rare congenital disorder of the connective tissue, leading to thoracic aortic aneurysms (TAA) and dissection, among other complications. Currently, the most efficient strategy to prevent life-threatening dissection is preventive surgery. Periodic imaging applying complex techniques is required to monitor TAA progression and to guide the timing of surgical intervention. Thus, there is an acute demand for non-invasive biomarkers for diagnosis and prognosis, as well as for innovative therapeutic targets of MFS. Unraveling the intricate pathomolecular mechanisms underlying the syndrome is vital to address these needs. High-throughput platforms are particularly well-suited for this purpose, as they enable the integration of different datasets, such as transcriptomic and epigenetic profiles. In this narrative review, we summarize relevant studies investigating changes in both the coding and non-coding transcriptome and epigenome in MFS-induced TAA. The collective findings highlight the implicated pathways, such as TGF-β signaling, extracellular matrix structure, inflammation, and mitochondrial dysfunction. Potential candidates as biomarkers, such as miR-200c, as well as therapeutic targets emerged, like Tfam, associated with mitochondrial respiration, or miR-632, stimulating endothelial-to-mesenchymal transition. While these discoveries are promising, rigorous and extensive validation in large patient cohorts is indispensable to confirm their clinical relevance and therapeutic potential.
Insights
Marfan syndrome (MFS) research identifies molecular targets for thoracic aortic aneurysms (TAA). Understanding transcriptome and epigenome changes offers potential non-invasive biomarkers and novel therapeutic strategies for MFS-T AA.
Area of Science:
- Genomics and Molecular Biology
- Cardiovascular Research
- Connective Tissue Disorders
Background:
- Marfan syndrome (MFS) is a rare genetic connective tissue disorder.
- It commonly leads to thoracic aortic aneurysms (TAA) and potentially life-threatening dissection.
- Current management relies on invasive imaging and preventive surgery, highlighting a need for better diagnostic and therapeutic approaches.
Purpose of the Study:
- To review current research on molecular mechanisms in MFS-associated TAA.
- To identify potential non-invasive biomarkers and therapeutic targets.
- To integrate findings from transcriptomic and epigenomic studies.
Main Methods:
- Narrative review of studies investigating coding and non-coding transcriptomes and epigenomes in MFS-induced TAA.
- Analysis of high-throughput data integration.
- Summary of implicated molecular pathways and candidate molecules.
Main Results:
- Key pathways implicated include TGF-β signaling, extracellular matrix remodeling, inflammation, and mitochondrial dysfunction.
- Potential biomarkers like miR-200c were identified.
- Therapeutic targets such as Tfam and miR-632 emerged, linked to mitochondrial function and endothelial-to-mesenchymal transition.
Conclusions:
- Transcriptomic and epigenomic alterations provide insights into MFS-TAA pathogenesis.
- Identified biomarkers and therapeutic targets show promise but require extensive validation in large patient cohorts.
- Further research is crucial for clinical translation and improved MFS management.
Related Concept Videos
Thoracic Aorta
Aortic Regurgitation I: Introduction
Aneurysm I: Introduction

